Who has invested in Freeline Therapeutics?

Syncona Ltd, UCL Technology Fund are named among the investors backing Freeline Therapeutics.

Freeline Therapeutics Funding: $160M Raised, Series B (2018)

Freeline Therapeutics funding overview

Freeline Therapeutics has raised $160M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in June 2018. The round record for Freeline Therapeutics runs through 2018; nothing later has been disclosed. Investors on record include Syncona Ltd, UCL Technology Fund. 2 distinct backers are named across the disclosed rounds.

Freeline Therapeutics at a glance

Total raised: $160M
Latest round: Series B
Latest round date: June 2018
Notable investors: Syncona Ltd, UCL Technology Fund

Frequently asked about Freeline Therapeutics funding

How much has Freeline Therapeutics raised?: Freeline Therapeutics has raised $160M in total disclosed funding across the rounds on record.
Who has invested in Freeline Therapeutics?: Syncona Ltd, UCL Technology Fund are named among the investors backing Freeline Therapeutics.
What was the latest Freeline Therapeutics funding round?: The most recent disclosed round is a Series B, announced in June 2018.
Where is Freeline Therapeutics based?: No headquarters location is disclosed for Freeline Therapeutics.
When did Freeline Therapeutics last raise?: The last disclosed Freeline Therapeutics round closed in June 2018 at Series B.

Freeline Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies below to benchmark round size and investor mix.

Freeline Therapeutics Funding: $160M Raised, Series B (2018)

Freeline Therapeutics funding overview

Freeline Therapeutics at a glance

Frequently asked about Freeline Therapeutics funding

Companies related to Freeline Therapeutics (31)

Browse related funding lists (3)